Discover the latest breakthroughs in oncology, including innovative treatments and FDA approvals that enhance patient care and outcomes in cancer therapy.
Targeted Oncology Staff
Articles by Targeted Oncology Staff
During a live event, Michael J. Overman, MD, discussed biomarker testing, ctDNA, and later-line treatment options for metastatic colorectal cancer.
During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.
During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.
During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.
Discover the latest breakthroughs in oncology, including FDA approvals and promising clinical trial results that offer hope for patients battling cancer.
During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.
During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.
September sees pivotal FDA approvals and designations, advancing innovative cancer treatments and reshaping oncology care for various malignancies.
During a live event, Michael C. Lowe, MD, MA, discussed how lifileucel provides an option for patients with unresectable or metastatic melanoma.
During a live event, Sara Nunnery, MD, MSCI, and participants discussed different chemotherapy agents that can be used with pembrolizumab in patients with metastatic triple-negative breast cancer.
Discover the latest oncology breakthroughs, including FDA approvals, promising trials, and advancements in cancer treatment strategies for improved patient outcomes.
During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.
During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell lymphoma.
During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.
During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.
Discover the latest breakthroughs in oncology, including FDA designations and promising therapies for ovarian, breast, head and neck, bladder, and renal cancers.
During a live event, Misty D. Shields, MD, PhD, discusses how trilaciclib reduces myelosuppression and other complications in small cell lung cancer.
During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.
During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in low-risk polycythemia vera.
During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.
During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.
During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.
Discover the latest breakthroughs in oncology, including promising therapies for breast, lung, and bladder cancers, enhancing patient outcomes and hope.
During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte study.
During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ribociclib in N0 and N1 breast cancer.
During a live event, Christopher J. Ferreri, MD, discussed findings on dose and schedule modifications of talquetamab in relapsed/refractory multiple myeloma.
During a live event, Michael R. Bishop, MD, discussed a case of steroid-refractory GVHD and the efficacy and safety outcomes from the ROCKstar trial.
Discover the latest breakthroughs in oncology, including FDA approvals and promising therapies that offer hope for cancer patients and clinicians alike.
During a live event, Christopher J. Ferreri, MD, discussed early- and late-presenting adverse events associated with talquetamab in relapsed/refractory multiple myeloma